Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Signaling

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited survival rates.
• Current treatments include surgery, radiation, and chemotherapy, but improved therapies are needed.
• Insulin-like growth factor 2 mRNA-binding protein 2 (Imp2) is implicated in various cancers, but its role in GBM is unclear.

Purpose of the Study:

• To investigate the role of Imp2 in the development and progression of glioblastoma multiforme.
• To elucidate the molecular mechanisms by which Imp2 influences GBM malignancy.
• To assess the therapeutic potential of targeting Imp2 in GBM.

Main Methods:

• Analysis of Imp2 expression in clinical GBM samples and public databases.
• In vitro studies involving gain and loss of Imp2 expression in GBM cell lines.
• Investigation of Imp2's regulation of Insulin-like growth factor 2 (IGF2) and PI3K/Akt signaling pathways.
• Assessment of Imp2 inhibition's effect on GBM cell proliferation, migration, invasion, EMT, and sensitivity to temozolomide.

Main Results:

• Imp2 is significantly upregulated in GBM tissues.
• Modulating Imp2 expression affects GBM cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT).
• Imp2 regulates IGF2 activity, leading to activation of the PI3K/Akt signaling pathway and promoting GBM malignancy.
• Inhibition of Imp2 enhances GBM cell sensitivity to temozolomide.

Conclusions:

• Imp2 plays a critical role in promoting GBM malignancy through the IGF2/PI3K/Akt pathway.
• Targeting Imp2 represents a potential therapeutic strategy for glioblastoma.
• These findings contribute to understanding GBM biology and may aid in developing more effective treatments.